1 INTRODUCTION
1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF WEIGHT LOSS AND OBESITY MANAGEMENT MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY
3.1 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET SNAPSHOT
3.2 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET REVENUE, 2017– 2025(US$ MN)

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS

5 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY DRUGS TYPE
5.1 OVERVIEW
5.2 PERIPHERALLY ACTING DRUGS
5.3 CENTRALLY ACTING DRUGS

6 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 OVERVIEW
6.2 HYPERMARKET/ SUPERMARKET
6.3 PHARMACEUTICAL STORES
6.4 ONLINE MARKET

7 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVER-THE-COUNTER DRUGS
7.3 PRESCRIPTION DRUGS

8 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY DURATION OF THERAPY
8.1 OVERVIEW
8.2 SHORT-TERM DRUGS
8.3 LONG-TERM DRUGS

9 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA

10 COMPETATIVE LANDSCAPE
10.1 OVERVIEW
10.2 NEW PRODUCT LAUNCHES

11 GLOBAL WEIGHT LOSS AND OBESITY MANAGEMENT MARKET, BY COMPANY
11.1 INTRODUCTION
11.2 OREXIGEN THERAPEUTICS INC.
11.2.1 BUSINESS OVERVIEW
11.2.2 PRODUCTS & SERVICES
11.2.3 KEY STRATEGY
11.2.4 RECENT DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.3 AMWAY ENTERPRISES
11.3.1 BUSINESS OVERVIEW
11.3.2 PRODUCTS & SERVICES
11.3.3 KEY STRATEGY
11.3.4 RECENT DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.4 NORGINE B.V.
11.4.1 BUSINESS OVERVIEW
11.4.2 PRODUCTS & SERVICES
11.4.3 KEY STRATEGY
11.4.4 RECENT DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.5 MERCK & CO. INC.
11.5.1 BUSINESS OVERVIEW
11.5.2 PRODUCTS & SERVICES
11.5.3 KEY STRATEGY
11.5.4 RECENT DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.6 PFIZER INC.
11.6.1 BUSINESS OVERVIEW
11.6.2 PRODUCTS & SERVICES
11.6.3 KEY STRATEGY
11.6.4 RECENT DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.7 ARENA PHARMACEUTICALS INC.
11.7.1 BUSINESS OVERVIEW
11.7.2 PRODUCTS & SERVICES
11.7.3 KEY STRATEGY
11.7.4 RECENT DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.8 GLAXOSMITHKLINE LIMITED
11.8.1 BUSINESS OVERVIEW
11.8.2 PRODUCTS & SERVICES
11.8.3 KEY STRATEGY
11.8.4 RECENT DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.9 NOVO NORDISK A/S
11.9.1 BUSINESS OVERVIEW
11.9.2 PRODUCTS & SERVICES
11.9.3 KEY STRATEGY
11.9.4 RECENT DEVELOPMENTS
11.9.5 SWOT ANALYSIS